2021 EAS/ESVM声明：外周动脉疾病患者的降脂或抗血栓治疗

2021-10-14 欧洲动脉硬化学会 Atherosclerosis

2021年10月，欧洲动脉硬化学会(EAS)联合欧洲血管医学学会(ESVM)共同发布了外周动脉疾病患者的降脂或抗血栓治疗声明。外周动脉疾病（PAD）患者发生心血管事件的风险非常高，但危险因素的管理通常

中文标题：

英文标题：

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

发布机构：

欧洲动脉硬化学会

发布日期：

2021-10-14

简要介绍：

2021年10月，欧洲动脉硬化学会(EAS)联合欧洲血管医学学会(ESVM)共同发布了外周动脉疾病患者的降脂或抗血栓治疗声明。外周动脉疾病（PAD）患者发生心血管事件的风险非常高，但危险因素的管理通常不理想。本文主要针对PAD的降脂或抗血栓治疗提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=4760c1c00226315a, title=2021 EAS/ESVM声明：外周动脉疾病患者的降脂或抗血栓治疗, enTitle=Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement, guiderFrom=Atherosclerosis, authorId=0, author=, summary=2021年10月，欧洲动脉硬化学会(EAS)联合欧洲血管医学学会(ESVM)共同发布了外周动脉疾病患者的降脂或抗血栓治疗声明。外周动脉疾病（PAD）患者发生心血管事件的风险非常高，但危险因素的管理通常, cover=https://img.medsci.cn/20211115/1636983874542_5579292.jpg, journalId=0, articlesId=null, associationId=64, associationName=欧洲动脉硬化学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Oct 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月，欧洲动脉硬化学会(EAS)联合欧洲血管医学学会(ESVM)共同发布了外周动脉疾病患者的降脂或抗血栓治疗声明。外周动脉疾病（PAD）患者发生心血管事件的风险非常高，但危险因素的管理通常不理想。本文主要针对PAD的降脂或抗血栓治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=6195, tagName=外周动脉疾病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=6195, guiderKeyword=外周动脉疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3490, appHits=145, showAppHits=0, pcHits=657, showPcHits=3344, likes=1, shares=18, comments=6, approvalStatus=1, publishedTime=Wed Nov 17 00:08:30 CST 2021, publishedTimeString=2021-10-14, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 15 21:48:15 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 00:27:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 EAS_ESVM声明：外周动脉疾病患者的降脂或抗血栓治疗.pdf)])

2021 EAS_ESVM声明：外周动脉疾病患者的降脂或抗血栓治疗.pdf

下载请点击：

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1205659, encodeId=5df3120565913, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b666569669, createdName=ms3000000424255294, createdTime=Thu Mar 24 20:15:23 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192965, encodeId=94d4119296544, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Sun Feb 13 14:44:28 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192180, encodeId=73bd1192180b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Fri Feb 11 08:35:49 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074203, encodeId=e90810e42035d, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:25 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070963, encodeId=bd5810e096380, content=非常实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec5f1303817, createdName=zhangcm2008, createdTime=Wed Nov 17 07:10:53 CST 2021, time=2021-11-17, status=1, ipAttribution=)]
2022-03-24 ms3000000424255294

实用

46 0
[GetPortalCommentsPageByObjectIdResponse(id=1205659, encodeId=5df3120565913, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b666569669, createdName=ms3000000424255294, createdTime=Thu Mar 24 20:15:23 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192965, encodeId=94d4119296544, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Sun Feb 13 14:44:28 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192180, encodeId=73bd1192180b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Fri Feb 11 08:35:49 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074203, encodeId=e90810e42035d, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:25 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070963, encodeId=bd5810e096380, content=非常实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec5f1303817, createdName=zhangcm2008, createdTime=Wed Nov 17 07:10:53 CST 2021, time=2021-11-17, status=1, ipAttribution=)]
2022-02-13 ms2000000789088268

好

48 0
[GetPortalCommentsPageByObjectIdResponse(id=1205659, encodeId=5df3120565913, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b666569669, createdName=ms3000000424255294, createdTime=Thu Mar 24 20:15:23 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192965, encodeId=94d4119296544, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Sun Feb 13 14:44:28 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192180, encodeId=73bd1192180b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Fri Feb 11 08:35:49 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074203, encodeId=e90810e42035d, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:25 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070963, encodeId=bd5810e096380, content=非常实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec5f1303817, createdName=zhangcm2008, createdTime=Wed Nov 17 07:10:53 CST 2021, time=2021-11-17, status=1, ipAttribution=)]
2022-02-11 ms2000000789088268

好

49 0
[GetPortalCommentsPageByObjectIdResponse(id=1205659, encodeId=5df3120565913, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b666569669, createdName=ms3000000424255294, createdTime=Thu Mar 24 20:15:23 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192965, encodeId=94d4119296544, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Sun Feb 13 14:44:28 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192180, encodeId=73bd1192180b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Fri Feb 11 08:35:49 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074203, encodeId=e90810e42035d, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:25 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070963, encodeId=bd5810e096380, content=非常实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec5f1303817, createdName=zhangcm2008, createdTime=Wed Nov 17 07:10:53 CST 2021, time=2021-11-17, status=1, ipAttribution=)]
2021-11-26 H8888888

不错学习了

65 0
[GetPortalCommentsPageByObjectIdResponse(id=1205659, encodeId=5df3120565913, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b666569669, createdName=ms3000000424255294, createdTime=Thu Mar 24 20:15:23 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192965, encodeId=94d4119296544, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Sun Feb 13 14:44:28 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192180, encodeId=73bd1192180b9, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83566493446, createdName=ms2000000789088268, createdTime=Fri Feb 11 08:35:49 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074203, encodeId=e90810e42035d, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:25 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070963, encodeId=bd5810e096380, content=非常实用！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec5f1303817, createdName=zhangcm2008, createdTime=Wed Nov 17 07:10:53 CST 2021, time=2021-11-17, status=1, ipAttribution=)]
2021-11-17 zhangcm2008

非常实用！

53 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 EAS/ESVM声明：外周动脉疾病患者的降脂或抗血栓治疗

相关指南

拓展阅读

科室

工具

服务